Development of a Gene and Oligonucleotide Delivery System
Award amount
$322,946Program and phase
STTR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- 2015-09-01
- Contract end date
- 2016-08-31
- UEI
- R1JMHFESEKD5
- Solicitation number
- PA14-308
- Topic code
- NCATS
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing
- A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production
- Development of CIL-0X: A Platform to Enhance Delivery of Inhaled RNA Therapeutics to Lung Cells
- Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
- Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense